Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.30 |
| ▸ | EED | O75530 | 1/20 | 0.30 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.30 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.30 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.30 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19170954 | 0.91 | LMNA (0.34) | LMNANPBWR1ALDH1A1MCOLN3EED | |
| SCHEMBL19163453 | 0.91 | MCOLN3 (0.40) | LMNAALDH1A1MCOLN3 | |
| SCHEMBL17458949 | 0.77 | PKM (0.45) | LMNAALDH1A1MCOLN3 | |
| SCHEMBL19222890 | 0.71 | CRHR1 (0.39) | LMNAALDH1A1CRHR1 | |
| SCHEMBL19170898 | 0.70 | CRHR1 (0.39) | LMNAFPR2PROKR1CRHR1 | |
| SCHEMBL6155541 | 0.70 | LMNA (0.40) | LMNANPBWR1ALDH1A1MCOLN3PTGS2 | |
| SCHEMBL17458924 | 0.69 | LMNA (0.40) | LMNAALDH1A1PTGS2 | |
| SCHEMBL19170534 | 0.69 | LMNA (0.47) | LMNANPBWR1ALDH1A1PTGS2EED | |
| SCHEMBL17458967 | 0.69 | LMNA (0.44) | LMNANPBWR1MCOLN3PTGS2 | |
| SCHEMBL19170350 | 0.67 | KDM4E (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | LMNA 2878/4885NPBWR1 4025/4885ALDH1A1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.